10x Genomics, Inc.

Informe acción NasdaqGS:TXG

Capitalización de mercado: US$2.1b

10x Genomics Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de 10x Genomics de 13.3% y 5.8% por año respectivamente. Se prevé que el BPA crezca en un 14.3% al año. Se espera que la rentabilidad financiera sea de -13.9% en 3 años.

Información clave

13.3%

Tasa de crecimiento de los beneficios

14.3%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Life Sciences18.4%
Tasa de crecimiento de los ingresos5.8%
Rentabilidad financiera futura-13.9%
Cobertura de analistas

Good

Última actualización30 Oct 2024

Actualizaciones recientes sobre el crecimiento futuro

Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts

Nov 01
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts

Recent updates

Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts

Nov 01
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts

10x Genomics: Deciphering The Preliminary Q3 Earnings

Oct 12

The Price Is Right For 10x Genomics, Inc. (NASDAQ:TXG) Even After Diving 28%

Oct 11
The Price Is Right For 10x Genomics, Inc. (NASDAQ:TXG) Even After Diving 28%

10x Genomics Is Still A Long Way From Profitability

Oct 03

We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Sep 09
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump

Aug 10
Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump

10x Genomics Stock Slips As Illumina Snaps Up Competitor - Tough Times Ahead

Jul 10

10x Genomics: Sticking To The Plan To Avoid The Falling The Knife

Jun 21

Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper

Jun 14
Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper

10x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business

May 21
10x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business

Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price

Apr 15
Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Feb 05
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

10x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses

Jan 20

Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

Dec 22
Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Nov 03
We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Aug 04
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

Jun 04
Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

Apr 29
At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

Mar 24
10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Feb 02
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

Jan 12
Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

Dec 22
An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:TXG - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
FechaIngresosBeneficiosFlujo de caja libreFlujo de caja operativoNúm. de analistas medio
12/31/2026694-99-247012
12/31/2025635-149-945816
12/31/2024599-171-1631916
9/30/2024630-1832539N/A
6/30/2024632-240-33-8N/A
3/31/2024625-264-74-27N/A
12/31/2023619-255-65-15N/A
9/30/2023591-223-113-27N/A
6/30/2023568-172-118-11N/A
3/31/2023536-174-126-17N/A
12/31/2022516-166-165-34N/A
9/30/2022504-167-161-42N/A
6/30/2022498-142-161-58N/A
3/31/2022499-89-129-38N/A
12/31/2021490-58-123-21N/A
9/30/2021459-455-253-157N/A
6/30/2021406-504-264-187N/A
3/31/2021333-533-289-219N/A
12/31/2020299-543-256-218N/A
9/30/2020262-134-104-81N/A
6/30/2020251-78-46-11N/A
3/31/2020264-49-1923N/A
12/31/2019246-31-835N/A
9/30/2019221-100-62-23N/A
6/30/2019197-105-69-43N/A
3/31/2019170-105-71-57N/A
12/31/2018146-112-83-76N/A
12/31/201771-19N/A-11N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que TXG siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que TXG siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que TXG siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (5.8% al año) de TXG crezcan más despacio que el mercado de US (8.8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 5.8% al año) de TXG crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: TXG se prevé que no sea rentable en 3 años.

Descubre empresas en crecimiento

7D

1Y

7D

1Y

7D

1Y